We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Essential Therapeutics (ETRX) formerly Microcide (MCDE
An SI Board Since January 1998
Posts SubjectMarks Bans Symbol
415 15 0 ETRX
Emcee:  John O'Neill Type:  Unmoderated
Microcide is postioned well in a key biotech area--finding solutions to antibiotic resistant bacteria. This area has been overlooked in the last decade, with most the emphasis on viral/AIDS research. Now we have strains of bacteria which are resistant to all antibiotics, including the "silver bullet" Vancomycin.

MCDE has the management and techical ability to accomplish the task--it's better positioned than any other company as a pure play in this area of biotech.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
415Essential Therapeutics Announces the Effectiveness of its Plan of ReorganizationSemiBull-10/21/2003
414WALTHAM, Mass., May 2 /PRNewswire-FirstCall/ -- Essential Therapeutics, Inc. (OTnigel bates-5/2/2003
413Essential Therapeutics to Develop Reorganization Plan Tuesday April 22, 7:06 amSemiBull-4/22/2003
412Essential Therapeutics Announces Delisting of its Common Stock from Nasdaq FridSemiBull-4/13/2003
411They got anything for this??? DAKLLCF-3/14/2003
410Essential Therapeutics Announces Nasdaq Panel Hearing Date and Its Plans To DiveSemiBull-3/4/2003
409BOSTON CAPITAL - A big gun in tough spot By Steven Syre, Globe Columnist, 2/1sim1-2/14/2003
408Essential Therapeutics Directors Aldrich, Walker Resign Monday February 10, 11:SemiBull-2/10/2003
407Essential Therapeutics Announces Results of Stockholder Meeting Thursday JanuarSemiBull-1/23/2003
406WALTHAM, Mass., Jan. 15 /PRNewswire-FirstCall/ -- Essential Therapeutics, Inc. (nigel bates-1/15/2003
405>>WALTHAM, Mass., Jan. 6 /PRNewswire-FirstCall/ -- Essential Therapeutics,tuck-1/6/2003
404Well, I guess that deals with the debt. Cash per share doesn't look quite sonigel bates-11/13/2002
40380M shares to be issued. Ouch! Press Release Source: Essential Therapeutics, Irkrw-11/13/2002
402<i>cash per share is north of 2 bucks. Apparently the Street thinks it'nigel bates-11/7/2002
401Wow, cash per share is north of 2 bucks. Apparently the Street thinks it'lltuck-11/6/2002
400Martha J. Carter Joins Essential Therapeutics as Senior Vice President of RegulaSemiBull-10/6/2002
399MARLBOROUGH, Mass.--(BUSINESS WIRE)--Aug. 21, 2002--Cetek Corporation announced nigel bates-8/21/2002
398Timothy Noyes Named Chief Operating Officer at Essential Therapeutics, Inc. WALSemiBull-8/15/2002
397Essential Therapeutics Enters Collaborative Agreement With Fujisawa PharmaceuticSemiBull-8/11/2002
396Spotfire, Iconix Open Analytical Window on Interaction of Chemicals and the HumaSemiBull-8/5/2002
395Essential Therapeutics' Parenteral Cephalosporin Enters Phase I Clinical Trinigel bates-7/25/2002
394Iconix Establishes Toxicity Markers and Predictive Signatures Using DrugMatrix SemiBull-6/13/2002
393Essential Therapeutics to shut programs, cut jobs WALTHAM, Mass., June 10 (ReutSemiBull-6/10/2002
392WALTHAM, Mass., June 10 /PRNewswire-FirstCall/ -- Essential Therapeutics, Inc. (nigel bates-6/10/2002
391Iconix Announces Appointment of Jim Neal as CEO Message 17568737SemiBull-6/6/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):